The Motley Fool published an article on May 22 titled "The 1 Tech Stock I Keep Adding To on Red Days - and Why I'll Do It Again." The stock is VisionSys AI (NASDAQ: VSA). The author frames it as an AI-powered company with a market cap below $1 billion, presenting a dip-buying opportunity.
Here is what VisionSys AI actually is.
The name change tells you everything.
VisionSys AI was formerly TCTM Kids IT Education Inc. - a Beijing-headquartered company that taught coding to children in China. That business, like most edtech plays in China during the regulatory crackdown, collapsed. The company divested its education units in 2024 and changed its name in September 2025. It now says it is a brain-computer interface company. It has not shipped a BCI product. It has not earned a dollar of revenue from BCI.
A company that pivots from failed kids' tutoring to brain implants is not an "AI stock." It is a shell with a new pitch deck. Any astute investor would have recognized that a name change is not a product strategy.
$149,000 in annual revenue.
VisionSys AI reported $149,000 in total revenue for fiscal year 2025. Not $149 million. Not $149K in BCI revenue. $149,000 total - from whatever residual operations survived the education divestiture. The company is unprofitable, with losses narrowing at roughly 30% per year over the last five years. That sounds like improvement until you realize that a 30% reduction from a tiny loss base is arithmetic, not a turnaround.
The company has negative equity. Its liabilities exceed its assets. If you liquidated VisionSys AI today, there is nothing left for shareholders. That is not a dip-buying opportunity. That is insolvency with a ticker symbol.
The $90 million raise at five times the market price.
On April 27, VisionSys AI announced it was in "advanced discussions" for a $90 million strategic investment priced at $1.50 per share. As of May 22, the stock was trading at roughly $0.31. The company wants to sell new shares at five times the market price to fund "core BCI algorithms and system platforms."
That is not an investment opportunity for the current shareholder - it is a dilution event waiting to happen. At $1.50 per share, the company would issue 60 million new shares into an outstanding pool of 567 million shares, according to its latest 20-F filing. Existing shareholders get diluted. If the deal fails because no investor pays that premium, the company burns cash longer. Either way, the existing shareholder loses.
Two reverse splits in six months.
VisionSys AI executed a 1-for-50 reverse split in December 2025. On May 5, it announced another 1-for-10 reverse ADS split effective May 26, 2026. Two reverse splits in under six months.
Reverse splits do not fix business fundamentals. They are cosmetic exercises designed to meet the Nasdaq's minimum bid price requirement of $1.00 and avoid delisting. When a company falls below the threshold, it gets a compliance period. When it reverse-splits to pop back above it, it buys time. VisionSys AI has been buying time since 2024.
What is the BCI story worth?
VisionSys AI's pitch is anchored to the brain-computer interface boom - an implantable device that connects the brain to external electronics, the same category Neuralink competes in. China does have an active BCI scene. A March 2026 report from BCIIntel noted China had 14 invasive BCI products under development compared to 5 in the US. But product development and commercial revenue are not the same thing. Neuralink itself, with billions in funding from Elon Musk, has not yet produced revenue.
VisionSys AI has no disclosed clinical trial, no regulatory filing with China's NMPA or the FDA, and no peer-reviewed publication establishing its algorithmic claims. The company plans to spend $90 million on "core BCI algorithms" - a phrase designed to sound technical while revealing nothing about what the company has actually built.
It is not as good as it looks. It isn't even close.
The cross-currents.
The cross-currents are straightforward here:
- The bull case: If the $90 million investment closes and the BCI program produces a defensible product within the next 3–5 years, the stock could re-rate from its current penny level. This requires the product to ship, get regulatory clearance, and generate revenue - none of which has happened.
- The reality check: The company has $149,000 in revenue, negative equity, and has needed two reverse splits in six months to stay listed. The $90 million raise is priced 5× above market, which suggests the capital raising itself is unlikely to close at those terms.
- Directional judgment: The weight of evidence points to downside. A company that cannot sustain its original business model, has not demonstrated BCI engineering capability, and requires repeated reverse splits to avoid delisting is not a dip-buying candidate. It is a value trap wearing an AI costume.
You decide which was marketing fluff and which one was analysis.